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Department of Biochemistry and Molecular Biology, New York Medical College, 15 Dana Road, Valhalla, NY 10595, United StatesAccording to the National Brain Tumor Society, over 120 different
types of human brain tumors have been described, the most common
of which are gliomas arising from glial (supportive) cells. Approximate-
ly two-thirds of brain tumors are benign, but about one third aremalig-
nant. Themost common adult-onset primary (i.e., arising from the brain
itself) malignant brain tumor is glioblastoma multiforme (GBM), ac-
counting for about 20% of all intracranial tumors. Because by the time
the cancer is discovered the tumor has usually metastasized to other
parts of the brain, it is extremely rare for the patient to be cured by sur-
gical resectioning. Thus, in addition to surgery, ﬁrst lines of defense are
radiation therapy, anti-angiogenic agents and chemotherapy. Despite
these heroic efforts the prognosis is grim, with GBM patients often
dying within months of ﬁrst diagnosis. In a recent study of 503 patients
it was shown that median survival time is 25 months after ﬁrst diagno-
sis and 12 months after ﬁrst resectioning (Ringel et al., 2015). In other
studies, median survival was reported to be 15 months for newly-
diagnosed GBM and 5-7 months for recurrent/relapsed GBM (reviewed
by Henriksson et al., 2011). Current standard of care (radiotherapy
plus temozolomide followed by 6 cycles of adjuvant temozolomide)
provides 2- and 5-year survival rates of 27 and 10% for patients with
newly diagnosed GBM (Stupp et al., 2009). The annual incidence
(as of 2008) in the “World Standard Population” is estimated to be
3.8/100,000 inmales, 3.1 in females, but slightly higher in the developed
world, and with a median age of onset of about 64 years (Ahmed et al.,
2014).Mean survival time following diagnosis of patients with GBMhas
improved only marginally within the last 50 years. Thus, new strategies
to treat GBM are urgently needed.
Thework by Sharpe et al. (2015–in this issue)may provide just such
a strategy. The rationale is relatively simple yet elegant. DNA repair
mechanisms inmitochondria are limited and are not active in cells con-
taining damaged mitochondrial DNA (mtDNA). Inasmuch as intact mi-
tochondria are essential for the maintenance of cellular function and
replication of cancer stem cells, these organelles may be particularly
useful targets in cancer therapy (Deus et al., 2015). Monoamine
oxidase-B (MAOB) in the brain is highly enriched in glial mitochondria
(Ekblom et al., 1993). Moreover, MAOB levels are higher in the mito-
chondria of glioblastoma cells compared to those of normal astrocytes.
Therefore, MAOB is a potential chemotherapeutic target in glioblastoma
cells.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.08.013.
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(MPTP) crosses the blood–brain-barrier (BBB) and is oxidized by
MAOB to 1-methyl-4-phenyl-2,3-dihydropyridinium(MPDP+), followed
by a second oxidation catalyzed by Coenzyme Q to 1-methyl-4-
phenylpyridinium (MPP+) — a neurotoxin that targets the substantia
nigra and causes Parkinson-like symptoms in humans and experimen-
tal animals (e.g., Hare et al., 2013). Sharpe et al. have designed a com-
pound that incorporates a “seeker” moiety similar to MPTP, but which,
unlike MPTP, is not noticeably toxic to normal neural cells, and which
carries a nitrogen mustard “warhead” [−N(CH2CH2Cl)2]. This compound
is N,N-bis(2-chloroethyl)-2-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)
propanamide (MP-MUS), which was shown to be an excellent sub-
strate of MAOB and more selective toward MAOB than toward MAOA.
MP-MUS, in a similar fashion to MPTP, readily crosses the BBB and is
consecutively oxidized by MAOB and Coenzyme Q to a pyridinium com-
pound (in this case, P+-MUS). P+-MUS, like MPP+, is highly lipophilic
and accumulates in the mitochondrial matrix (Sharpe et al., 2015a).
Loss of chloride ion from P+-MUS results in conversion of the mustard
moiety to a highly reactive substituent (either a 3-membered aziridinium
or a 5-membered dihydrooxazolium), which has the ability to cause
massive oxidative stress and DNA breaks in the targeted mitochondria
(Sharpe et al., 2015–in this issue).
Preliminary ﬁndings withMP-MUS reported by Sharpe et al. (2015–
in this issue) are highly encouraging. The authors showed that incubat-
ing cultures of human glioblastoma cells withMP-MUS signiﬁcantly de-
creased the mitochondrial membrane potential, whereas selegiline, a
speciﬁc inhibitor of MAOB, did not. Treatment with MP-MUS resulted
in an increase inmtDNA damage, an increase in reactive oxygen species
(ROS) and an increase in MAOB — until the cells began to die. In re-
sponse to MP-MUS treatment, the cells upregulated mitochondrial
biogenesis, but the mitochondria were poorly energized and cell viabil-
ity declined. Incubation of the human glioblastoma cells with selegiline
protected against the toxic effects of MP-MUS, indicating that the
cellular/mitochondrial damage is indeed due to activation of the
MP-MUS prodrug to a mitochondrial toxicant via the action of MAOB.
In a second series of experiments, Sharpe et al. investigated the effect
of MP-MUS treatment on primary human glioma xenografts in a Nu/Nu
mouse model. Tumor volumes shrank in the MP-MUS treatment group
after the ﬁrst injection, whereas tumors grew steadily in the saline-
treated controls, and, interestingly, tumors could not be detected in two
of the MP-MUS-treated animals. No evidence was found for Parkinson-
like symptoms or damage to the substantia nigra in theMP-MUS-treated
mice. The xenografts thatwere not completely destroyedby theMP-MUS
treatment exhibited marked increases in MAOB, ROS, oxidative stressthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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mice. No organ speciﬁc toxicities were noted for MP-MUS-treated mice.
Finally, the authors investigated the effects ofMP-MUS onmorbidity
and mortality in an intracranial mouse model of primary human GBM.
Primary human GBM cells encased in a Matrigel matrix were injected
into one hemisphere of NOD/SCID mice. The ﬁrst of three tail-vein
injections of saline MP-MUS was carried out on day 115 post-
engraftment. By day 248, 50% of the control mice had died, whereas
none of the MP-MUS-treated had died, with only one of the treated
mice exhibiting symptoms during the entire study period. Moreover,
inﬁltration of the human GBM cells into the contralateral hemisphere
was noted in 10 of 11 control mice. In contrast, GBM cells were noted
in the ipsilateral hemispheres of only 6 of the 11 treated mice, but no
GBM cell inﬁltrates were noted in their contralateral hemispheres.
In conclusion, Sharpe et al. have demonstrated that MP-MUS is re-
markably selective, targeting the mitochondria via MAOB of human
glioblastoma cells both in culture and in vivo, with no discernible
organ toxicity. As the authors note, the upregulation of MAOB in the
cancer cells is a maladaptive response, which may actually increase
the effectiveness of MP-MUS as a chemotherapeutic agent. The authors
indicate that additional work is under way to perform more detailed
toxicological/pharmacodynamic tests and to ﬁne-tune the manufactur-
ing process, and perhaps design additional warheads. The authors' con-
cluding words are: “we are hopeful to see this drug in clinical trials in
the next 18 months”. Based on the preliminary data presented by
Sharpe et al., MP-MUS is a lead compound in a new strategy that prom-
ises to be highly effective in combating the terrible scourge of GBM.
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